GUNN & Co INVESTMENT MANAGEMENT INC. Buys 675,728 Shares of Kenvue Inc. (NYSE:KVUE)

GUNN & Co INVESTMENT MANAGEMENT INC. boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 1,297.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 727,824 shares of the company’s stock after buying an additional 675,728 shares during the quarter. GUNN & Co INVESTMENT MANAGEMENT INC.’s holdings in Kenvue were worth $15,670,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Commonwealth Equity Services LLC purchased a new position in shares of Kenvue during the third quarter valued at approximately $5,053,000. Cambridge Investment Research Advisors Inc. bought a new position in Kenvue in the 3rd quarter valued at $1,809,000. Raymond James Financial Services Advisors Inc. increased its stake in Kenvue by 1,089.1% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 582,662 shares of the company’s stock worth $11,700,000 after purchasing an additional 533,660 shares during the period. Stratos Wealth Partners LTD. bought a new stake in shares of Kenvue during the third quarter worth $982,000. Finally, Brown Advisory Inc. purchased a new stake in shares of Kenvue during the third quarter valued at $26,068,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.4 %

KVUE opened at $19.20 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average is $19.82 and its two-hundred day moving average is $20.12. Kenvue Inc. has a 1 year low of $17.82 and a 1 year high of $27.80.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. Sell-side analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.17%. The ex-dividend date of this dividend is Tuesday, May 7th.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target on the stock. William Blair started coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating for the company. JPMorgan Chase & Co. dropped their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Sanford C. Bernstein started coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. Finally, Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average price target of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.